$SLDB
Solid Biosciences Inc.

2019 Q1 Form 10-K Financial Statement

#000156459019007462 Filed on March 13, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q4 2017 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.030M $4.620M $3.220M
YoY Change 74.01% 43.48% 95.15%
% of Gross Profit
Research & Development $23.27M $17.76M $11.95M
YoY Change 95.06% 48.62% 69.02%
% of Gross Profit
Depreciation & Amortization $596.0K $480.0K $220.0K
YoY Change 162.56% 118.18% 450.0%
% of Gross Profit
Operating Expenses $30.30M $22.39M $15.16M
YoY Change 89.71% 47.66% 73.86%
Operating Profit -$30.30M -$22.39M -$15.16M
YoY Change 89.71% 47.66%
Interest Expense $510.0K $380.0K $580.0K
YoY Change 628.57% -34.48% 480.0%
% of Operating Profit
Other Income/Expense, Net $720.0K $80.00K $90.00K
YoY Change 650.0% -11.11% -10.0%
Pretax Income -$29.58M -$21.92M -$14.49M
YoY Change 86.27% 51.28% 70.07%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$29.58M -$21.92M -$14.49M
YoY Change 86.32% 51.31% 86.69%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$850.5K -$632.6K -$449.6K
COMMON SHARES
Basic Shares Outstanding 35.42M 35.43M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q4 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $94.70M $122.5M $69.09M
YoY Change -48.08% 77.24%
Cash & Equivalents $54.32M $86.37M $52.08M
Short-Term Investments $40.80M $36.10M $17.01M
Other Short-Term Assets $7.000M $6.200M $1.600M
YoY Change 250.0% 287.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $101.8M $128.6M $70.66M
YoY Change -44.79% 82.06%
LONG-TERM ASSETS
Property, Plant & Equipment $12.00M $10.42M $2.429M
YoY Change 171.5% 329.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $209.0K $209.0K $3.100M
YoY Change 0.0% -93.26%
Total Long-Term Assets $18.41M $10.96M $5.535M
YoY Change 278.56% 97.98%
TOTAL ASSETS
Total Short-Term Assets $101.8M $128.6M $70.66M
Total Long-Term Assets $18.41M $10.96M $5.535M
Total Assets $120.2M $139.6M $76.19M
YoY Change -36.48% 83.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.400M $3.691M $5.066M
YoY Change -7.46% -27.14%
Accrued Expenses $8.700M $8.235M $5.972M
YoY Change 112.61% 37.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $200.0K $200.0K
YoY Change
Total Short-Term Liabilities $14.57M $12.48M $11.27M
YoY Change 46.79% 10.74%
LONG-TERM LIABILITIES
Long-Term Debt $800.0K $900.0K $0.00
YoY Change
Other Long-Term Liabilities $5.700M $1.074M
YoY Change 1461.64%
Total Long-Term Liabilities $6.500M $1.074M $0.00
YoY Change 1680.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.57M $12.48M $11.27M
Total Long-Term Liabilities $6.500M $1.074M $0.00
Total Liabilities $21.10M $14.41M $11.27M
YoY Change 105.01% 27.89%
SHAREHOLDERS EQUITY
Retained Earnings -$228.6M -$199.1M -$124.3M
YoY Change 63.16% 60.2%
Common Stock $327.7M $324.2M
YoY Change 2.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $99.11M $125.2M -$59.26M
YoY Change
Total Liabilities & Shareholders Equity $120.2M $139.6M $76.19M
YoY Change -36.47% 83.21%

Cashflow Statement

Concept 2019 Q1 2018 Q4 2017 Q4
OPERATING ACTIVITIES
Net Income -$29.58M -$21.92M -$14.49M
YoY Change 86.32% 51.31% 86.69%
Depreciation, Depletion And Amortization $596.0K $480.0K $220.0K
YoY Change 162.56% 118.18% 450.0%
Cash From Operating Activities -$25.93M -$21.41M -$13.98M
YoY Change 50.98% 53.15% 150.99%
INVESTING ACTIVITIES
Capital Expenditures $1.953M -$1.440M -$330.0K
YoY Change 95.1% 336.36% 106.25%
Acquisitions
YoY Change
Other Investing Activities -$4.490M -$19.83M -$2.390M
YoY Change 636.07% 729.71% -141.14%
Cash From Investing Activities -$6.445M -$21.26M -$2.710M
YoY Change 300.06% 684.5% -147.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -10.00K 53.76M
YoY Change -100.0% -100.02% 1471.93%
NET CHANGE
Cash From Operating Activities -25.93M -21.41M -13.98M
Cash From Investing Activities -6.445M -21.26M -2.710M
Cash From Financing Activities 0.000 -10.00K 53.76M
Net Change In Cash -32.37M -42.68M 37.07M
YoY Change -128.67% -215.13% 959.14%
FREE CASH FLOW
Cash From Operating Activities -$25.93M -$21.41M -$13.98M
Capital Expenditures $1.953M -$1.440M -$330.0K
Free Cash Flow -$27.88M -$19.97M -$13.65M
YoY Change 53.41% 46.3% 152.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Trading Symbol
TradingSymbol
sldb
CY2018 dei Entity Registrant Name
EntityRegistrantName
Solid Biosciences Inc.
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35422915
CY2018Q2 dei Entity Public Float
EntityPublicFloat
598700000
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86366000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52080000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
36098000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
17014000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6175000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1499000
CY2017Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
65000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
128639000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
70658000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10422000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2429000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
209000
CY2018Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
327000
CY2017Q4 sldb Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
3106000
CY2018Q4 us-gaap Assets
Assets
139597000
CY2017Q4 us-gaap Assets
Assets
76193000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3691000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5066000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8235000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5972000
CY2018Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
173000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
382000
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
233000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12481000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11271000
CY2018Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
859000
CY2017Q4 us-gaap Members Capital
MembersCapital
65014000
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
35000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
324209000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-13000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-199056000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-124258000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
125183000
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-59257000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
139597000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
76193000
CY2018Q4 us-gaap Common Unit Authorized
CommonUnitAuthorized
0
CY2017Q4 us-gaap Common Unit Authorized
CommonUnitAuthorized
20189509
CY2018Q4 us-gaap Common Unit Issued
CommonUnitIssued
0
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
129096000
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1803000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
889000
CY2016 us-gaap Profit Loss
ProfitLoss
-23773000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1001000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
271000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1679000
CY2017 us-gaap Profit Loss
ProfitLoss
-53178000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
270000
CY2016 us-gaap Operating Expenses
OperatingExpenses
25576000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-25576000
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001707502
CY2018 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2018 dei Entity Small Business
EntitySmallBusiness
false
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2018 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1074000
CY2018Q4 us-gaap Liabilities
Liabilities
14414000
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2017Q4 us-gaap Liabilities
Liabilities
11271000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
0
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
0
CY2018 us-gaap Profit Loss
ProfitLoss
-74798000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-52118000
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
619000
CY2016 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2234000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-74798000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-21539000
CY2016 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
-4309000
CY2017 sldb Redemption Of Redeemable Interest From Noncontrolling Interest
RedemptionOfRedeemableInterestFromNoncontrollingInterest
1925000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-74798000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-39317000
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17230000
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.88
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.14
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1698904
CY2016 us-gaap Investment Income Interest
InvestmentIncomeInterest
369000
CY2018 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-74790000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5330000
CY2018 us-gaap Revenues
Revenues
0
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57965000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17722000
CY2018 us-gaap Operating Expenses
OperatingExpenses
75687000
CY2017 us-gaap Operating Expenses
OperatingExpenses
54857000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-75687000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-54857000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10448000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4052000
CY2017 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2424000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
131507000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
77078000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
34548000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
44302000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52145000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7843000
CY2015Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28595000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86693000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
952000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21506000
CY2017Q4 us-gaap Common Unit Issued
CommonUnitIssued
19438552
CY2018Q4 us-gaap Common Unit Outstanding
CommonUnitOutstanding
0
CY2017Q4 us-gaap Common Unit Outstanding
CommonUnitOutstanding
19438552
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
0
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35432460
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35432460
CY2017 us-gaap Revenues
Revenues
0
CY2016 us-gaap Revenues
Revenues
0
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39905000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20116000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14952000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5460000
CY2017 sldb Revaluation Of Preferred Unit Tranche Rights
RevaluationOfPreferredUnitTrancheRights
459000
CY2016 sldb Revaluation Of Preferred Unit Tranche Rights
RevaluationOfPreferredUnitTrancheRights
1163000
CY2017 us-gaap Investment Income Interest
InvestmentIncomeInterest
219000
CY2017 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1060000
CY2017 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
959000
CY2017 sldb Redemption Of Preferred Units
RedemptionOfPreferredUnits
15685000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.25
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33262597
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13649485
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-36000
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
33000
CY2017 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-53214000
CY2016 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-23740000
CY2017 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-1060000
CY2016 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-2234000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-74790000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52154000
CY2016Q4 us-gaap Members Equity
MembersEquity
-37886000
CY2017 sldb Temporary Equity Increase Decrease To Redemption Value Adjustment
TemporaryEquityIncreaseDecreaseToRedemptionValueAdjustment
959000
CY2017Q4 us-gaap Members Equity
MembersEquity
-59257000
CY2018 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
124179000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5955000
CY2018 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
4592000
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
90000
CY2017 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-206000
CY2016 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-505000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
5955000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
5330000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
1470000
CY2018 us-gaap Depreciation
Depreciation
1566000
CY2017 us-gaap Depreciation
Depreciation
448000
CY2016 us-gaap Depreciation
Depreciation
56000
CY2018 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-4000
CY2017 sldb Loss Gain From Revaluation Of Preferred Unit Tranche Right
LossGainFromRevaluationOfPreferredUnitTrancheRight
-459000
CY2016 sldb Loss Gain From Revaluation Of Preferred Unit Tranche Right
LossGainFromRevaluationOfPreferredUnitTrancheRight
-1163000
CY2018 us-gaap Increase Decrease In Leasing Receivables
IncreaseDecreaseInLeasingReceivables
-823000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4930000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-815000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2005000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1610000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1579000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2213000
CY2018 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2883000
CY2017 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2035000
CY2016 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2577000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-70197000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43224000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20120000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7776000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2276000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
392000
CY2018 us-gaap Payments For Proceeds From Availableforsale Securities Shortterm
PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm
-25335000
CY2017 us-gaap Payments For Proceeds From Availableforsale Securities Shortterm
PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm
-31621000
CY2016 us-gaap Payments For Proceeds From Availableforsale Securities Shortterm
PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm
-22035000
CY2018 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
44321000
CY2017 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
18897000
CY2016 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
25695000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26762000
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2168000
CY2016 us-gaap Proceeds From Issuance Of Redeemable Preferred Stock
ProceedsFromIssuanceOfRedeemablePreferredStock
3420000
CY2018 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
133688000
CY2018 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
13000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3420000
CY2016 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20752000
CY2016 sldb Reclassification Of Preferred Liability Upon Settlement
ReclassificationOfPreferredLiabilityUponSettlement
10841000
CY2017 sldb Deferred Offering Costs Included In Accounts Payable And Accruals
DeferredOfferingCostsIncludedInAccountsPayableAndAccruals
682000
CY2016 sldb Deferred Offering Costs Included In Accounts Payable And Accruals
DeferredOfferingCostsIncludedInAccountsPayableAndAccruals
47000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
265000
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
116000
CY2018 sldb Property And Equipment Acquired Through Capital Leases
PropertyAndEquipmentAcquiredThroughCapitalLeases
1023000
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the recognition of research and development expenses and equity-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company&#8217;s estimates. </p>
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk and of Significant Suppliers </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and available-for-sale securities. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company maintains each of its cash, cash equivalents and available-for-sale securities balances with high-quality and accredited financial institutions and accordingly, such funds are not exposed to significant credit risk. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including clinical and pre-clinical testing. These programs could be adversely affected by a significant interruption in the supply of such drug substance products. </p>
CY2018Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2017Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1153198
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1153198
CY2018Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
122464000
CY2018Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
0
CY2017Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
0
CY2018Q4 sldb Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
0
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7678000
CY2016Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
165000
CY2018Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
54423000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
36098000
CY2018Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
90521000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
17014000
CY2018Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2017Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2018Q4 sldb Fair Value Assets Level3 To Level1 Transfers Amount
FairValueAssetsLevel3ToLevel1TransfersAmount
0
CY2017Q4 sldb Fair Value Assets Level3 To Level1 Transfers Amount
FairValueAssetsLevel3ToLevel1TransfersAmount
0
CY2018Q4 sldb Fair Value Assets Level1 To Level3 Transfers Amount
FairValueAssetsLevel1ToLevel3TransfersAmount
0
CY2017Q4 sldb Fair Value Assets Level1 To Level3 Transfers Amount
FairValueAssetsLevel1ToLevel3TransfersAmount
0
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
36103000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7000
CY2017Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
17027000
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
13000
CY2017Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
17027000
CY2018Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
36103000
CY2017Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
17014000
CY2018Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
36098000
CY2018 sldb Available For Sale Securities Weighted Average Maturity Period
AvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P3M18D
CY2017 sldb Available For Sale Securities Weighted Average Maturity Period
AvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P4M24D
CY2018Q4 sldb Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
4365000
CY2017Q4 sldb Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
951000
CY2018Q4 sldb Prepaid Expense And Other Assets Miscellaneous Current
PrepaidExpenseAndOtherAssetsMiscellaneousCurrent
1810000
CY2017Q4 sldb Prepaid Expense And Other Assets Miscellaneous Current
PrepaidExpenseAndOtherAssetsMiscellaneousCurrent
548000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12410000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2933000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1988000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
504000
CY2017Q4 sldb Common Unit Issued And Outstanding
CommonUnitIssuedAndOutstanding
19438552
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1185207
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
32009
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
0
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
28.51
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
20.80
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.73
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
28.73
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5955000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5330000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1470000
CY2018Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
2210000
CY2018Q4 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
2293000
CY2018Q4 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
1508000
CY2018Q4 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
278000
CY2018Q4 us-gaap Contractual Obligation
ContractualObligation
8621000
CY2018Q2 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
1320000
CY2018 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2017 sldb Accretion Decretion Of Preferred Units To Redemption
AccretionDecretionOfPreferredUnitsToRedemption
-959000
CY2016 sldb Accretion Decretion Of Preferred Units To Redemption
AccretionDecretionOfPreferredUnitsToRedemption
4309000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1896762
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1404265
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
19150000
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
22386000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-15973000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18178000
CY2018Q4 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
2332000
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1104391
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.055
CY2018 sldb Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.008
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.092
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Exempt Income
EffectiveIncomeTaxRateReconciliationTaxExemptIncome
0.017
CY2018 sldb Effective Income Tax Rate Reconciliation Change In Filling Status Of Corporation
EffectiveIncomeTaxRateReconciliationChangeInFillingStatusOfCorporation
0.005
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.336
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16417000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
6903000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
372000
CY2018Q4 sldb Deferred Tax Assets Tax Deferred Accrued Expense
DeferredTaxAssetsTaxDeferredAccruedExpense
935000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
856000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
177000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
25660000
CY2018Q4 sldb Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
406000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
25254000
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2018Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2018Q1 us-gaap Revenues
Revenues
0
CY2018Q2 us-gaap Revenues
Revenues
0
CY2018Q3 us-gaap Revenues
Revenues
0
CY2018Q4 us-gaap Revenues
Revenues
0
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
15973000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
18178000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19150000
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-22386000
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-15877000
CY2018Q2 us-gaap Profit Loss
ProfitLoss
-17980000
CY2018Q3 us-gaap Profit Loss
ProfitLoss
-19020000
CY2018Q4 us-gaap Profit Loss
ProfitLoss
-21921000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-15877000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-17980000
CY2017Q1 us-gaap Revenues
Revenues
0
CY2017Q2 us-gaap Revenues
Revenues
0
CY2017Q3 us-gaap Revenues
Revenues
0
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-19020000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-21921000
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15877000
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17980000
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19020000
CY2018Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21921000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.55
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63
CY2017Q4 us-gaap Revenues
Revenues
0
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
14113000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
11887000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
13696000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
15161000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14113000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11887000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13696000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-15161000
CY2017Q1 us-gaap Profit Loss
ProfitLoss
-13875000
CY2017Q2 us-gaap Profit Loss
ProfitLoss
-11311000
CY2017Q3 us-gaap Profit Loss
ProfitLoss
-13505000
CY2017Q4 us-gaap Profit Loss
ProfitLoss
-14487000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-12815000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-11311000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-13505000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-14487000
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14000
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11311000
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13505000
CY2017Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14487000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.79
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.84

Files In Submission

Name View Source Status
0001564590-19-007462-index-headers.html Edgar Link pending
0001564590-19-007462-index.html Edgar Link pending
0001564590-19-007462.txt Edgar Link pending
0001564590-19-007462-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gcrbgde4am53000001.jpg Edgar Link pending
gcrbgde4am53000002.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sldb-10k_20181231.htm Edgar Link pending
sldb-20181231.xml Edgar Link completed
sldb-20181231.xsd Edgar Link pending
sldb-20181231_cal.xml Edgar Link unprocessable
sldb-20181231_def.xml Edgar Link unprocessable
sldb-20181231_lab.xml Edgar Link unprocessable
sldb-20181231_pre.xml Edgar Link unprocessable
sldb-ex1020_211.htm Edgar Link pending
sldb-ex102_215.htm Edgar Link pending
sldb-ex103_214.htm Edgar Link pending
sldb-ex104_213.htm Edgar Link pending
sldb-ex107_216.htm Edgar Link pending
sldb-ex108_217.htm Edgar Link pending
sldb-ex211_212.htm Edgar Link pending
sldb-ex231_10.htm Edgar Link pending
sldb-ex311_9.htm Edgar Link pending
sldb-ex312_8.htm Edgar Link pending
sldb-ex321_6.htm Edgar Link pending
sldb-ex322_7.htm Edgar Link pending